Related references
Note: Only part of the references are listed.Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
Li-Chun Lu et al.
LIVER CANCER (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Stacey Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Masafumi Ikeda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
M J Pishvaian et al.
ANNALS OF ONCOLOGY (2018)
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Fasiha Kanwal et al.
GASTROENTEROLOGY (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Tumor regulation of the tissue environment in the liver
Tobias Eggert et al.
PHARMACOLOGY & THERAPEUTICS (2017)
1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA
N.H. Segal et al.
ANNALS OF ONCOLOGY (2017)
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Mark Yarchoan et al.
CLINICAL CANCER RESEARCH (2017)
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Expanding antigen-specific regulatory networks to treat autoimmunity
Xavier Clemente-Casares et al.
NATURE (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The evolving epidemiology of hepatocellular carcinoma: a global perspective
Michael C. Wallace et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
Shukui Qin et al.
ONCOLOGIST (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Hepatocellular Carcinoma from an Immunologic Perspective
Tim F. Greten et al.
CLINICAL CANCER RESEARCH (2013)
Epidemiology of Hepatocellular Carcinoma Consider the Population
Sahil Mittal et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Hashem B. El-Serag
GASTROENTEROLOGY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma
M. C. Kew
PATHOLOGIE BIOLOGIE (2010)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome
Richard Todd Stravitz et al.
AMERICAN JOURNAL OF MEDICINE (2008)
Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts
G. Xia et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features
Sergio Rutella et al.
BLOOD (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10high IL-12absent dendritic cells with tolerogenic potential
GL Li et al.
JOURNAL OF IMMUNOLOGY (2005)
Dendritic cells and immune regulation in the liver
AH Lau et al.
GUT (2003)
Share Paper
